Are you a new member? Sign up now
Login area
| Sign up
close
KADCYLA - 160mg - 1
| ATC | B/G | Ingredients | code | Registration Nb | brand_name | Dosage | Presentation | Form | Route | Agent | Laboratory | man_country | Price | Pharmacist Margin | Startum | Responsible Party Name | Responsible Party Country | Exch_date | %SUBSIDY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| L01FD03 | BioTech | Trastuzumab emtansine - 160mg | 7754 | 63014/1 | KADCYLA | 160mg | 1 | Injectable powder for concentrate for solution | Infusion | Omnipharma | F. Hoffmann La Roche Ltd, Kaiseraugst | Switzerland | 216,872,714 L.L | 2.44 | E2 | F. Hoffmann La Roche Ltd | Switzerland | 2/5/2024 | 0 |
Drug Substitutes
| ATC | B/G | Ingredients | code | Registration Nb | brand_name | Dosage | Presentation | Form | Route | Agent | Laboratory | man_country | Price | Pharmacist Margin | Startum | Responsible Party Name | Responsible Party Country | Exch_date | %SUBSIDY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| L01FD03 | BioTech | Trastuzumab emtansine - 160mg | 7754/388 | 63014/1 | KADCYLA | 160mg | 1 | Injectable powder for concentrate for solution | Infusion | Omnipharma | F. Hoffmann La Roche Ltd, Kaiseraugst | Switzerland | L.L | 2.44 | E2 | F. Hoffmann La Roche Ltd | Switzerland | 2/5/2024 |
Sitemap
© Copyrights reserved to Ministry of Public Health 2024